AroCell Q4: Comments on the quarterly report - Redeye

Redeye notes a relatively decent quarter for AroCell, which is currently trading under our Bear Case with an EV reflecting considerably low sales multiples for the IDL Biotech product portfolio for the coming years. While the eventual recognition of this could act as a catalyst for the stock, we emphasize the rights issue’s outcome with a probable wet-blanket effect on the share price performance going forward.

Länk till analysen i sin helhet: https://www.redeye.se/research/834598/arocell-q4-comments-on-the-quarterly-report?utm_source=finwire&utm_medium=RSS